#ASCO22 – Estudo randomizado | Fluorouracil, leucovorina, oxaliplatina e irinotecano com panitumumabe vs. fluorouracil, leucovorina e oxaliplatina com panitumumabe para pacientes com câncer colorretal metastático tipo RAS/BRAF agressivo.

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO – Journal of Clinical Oncology